Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · AMANTA HEALTHCARE LIMITED · 28 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
Manufactures IV fluid bottles and Small Volume Parenterals (SVP) for pharmaceutical and healthcare use. The SteriPort range uses ISBM (Injection Stretch Blow Moulding) technology to make two-port IV fluid bottles and contributes 42% of FY26 revenue; a third SteriPort line is being commissioned to roughly double annual capacity. The SVP portfolio covers inhalation and ophthalmic products. Materials are the largest cost line at 33.7% of revenue, with polymer price increases of 60-70% passed through via 5-6% selling price increases. FY26 revenue stood at INR288 crore with EBITDA of INR63 crore (22% margin) and PAT of INR15 crore. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. SteriPort (42%), SVP and other products. Sterile parenteral pharmaceutical manufacturing (LVP and SVP)
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY26–FY26 (all audited; no estimate years)
₹ crore · standalone
FY26
Revenue
288
EBITDA (ex other income)
57
margin %
19.9
Owners' profit
15
EPS, as reported (₹)
4.33
ROE % · ROCE %
6.8 · 10.0
Debt / equity (x)
1.06
Cash from operations
48
Capex
(80)
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · AMANTA HEALTHCARE LIMITED · 28 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 5 quarters
₹ crore
Q1 FY26
Q2 FY26
Q3 FY26
Q4 FY26
Q1 FY27
Revenue
65
71
74
77
69
Profit before tax
5
2
6
8
4
Net profit
4
1
5
6
3
EPS (₹)
1.22
0.35
1.35
1.61
0.85
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
Company
M.cap ₹ cr
P/E
P/B
EV/EBITDA
ROE %
ROCE %
Rev CAGR 5y %
EBITDA m. %
SUN PHARMACEUTICAL IND L
4,20,165
34.8
5.01
22.5
13.7
17.5
11.8
32.3
DIVI S LABORATORIES LTD
2,51,896
86.3
15.03
65.0
15.3
18.8
8.7
42.8
TORRENT PHARMACEUTICALS L
1,56,538
73.9
8.90
38.9
12.2
8.0
11.8
33.1
ZYDUS LIFESCIENCES LTD
1,17,055
26.1
3.96
15.1
17.3
18.0
12.4
25.2
LAURUS LABS LIMITED
1,15,722
105.7
21.31
64.4
16.4
17.2
7.2
32.0
DR. REDDY S LABORATORIES
1,09,385
33.9
2.86
14.6
10.9
13.0
12.1
15.0
CIPLA LTD
1,09,060
32.3
3.16
16.7
11.2
14.7
8.0
19.7
MANKIND PHARMA LIMITED
1,03,353
50.6
6.24
28.4
11.7
10.8
—
27.3
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
Metric
Company
Group median
Rank
Better than
P/E (TTM)
38.2
30.1
101 of 158
36%
P/B
2.8
3.0
76 of 163
53%
ROCE
5.1
10.8
123 of 183
33%
ROE
6.8
9.8
107 of 166
36%
Debt / Equity
1.1
0.2
156 of 166
6%
EBITDA margin
22.1
17.5
67 of 165
60%
Revenue growth
5.3
16.3
113 of 161
30%
Profit growth
(5.6)
30.9
110 of 158
31%
Market cap
617
810
96 of 181
47%
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · AMANTA HEALTHCARE LIMITED · 28 October 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
Date · filing
Category
Importance
Next day %
5-day %
26 Oct 2026 · Board meeting set for November 3 financial results
board shareholder meetings
low
—
—
6 Oct 2026 · Reg 74(5) Certificate filed for Q2 FY26-27
compliance
minimal
—
—
5 Oct 2026 · Amanta Healthcare promoter group member gifts 4.46 percent stake to nephew
ownership changes
medium
—
—
1 Oct 2026 · Promoter group member gifts 99,600 shares to relative (0.26% of equity)
ownership changes
medium
—
—
1 Oct 2026 · Promoter group inter-se share transfer at Amanta Healthcare
ownership changes
medium
—
—
30 Sept 2026 · Promoter group members reshuffle shares via off-market transfer
16 Sept 2026 · Amanta Healthcare AGM: All 5 resolutions passed including MD pay revision
compliance
minimal
—
—
16 Sept 2026 · All 5 resolutions passed at Amanta Healthcare 31st AGM
board shareholder meetings
low
—
—
16 Sept 2026 · AGM approves director re-appointment and secretarial auditor
management changes
medium
—
—
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
Where a broker report shows
This document shows
Why
A rating (BUY / ADD / REDUCE / SELL)
A state: the latest filed quarter and the measured reactions
an event is a fact; a rating is an opinion that requires SEBI RA registration
A target price and upside
The current price and the multiples against the group
a target is a forecast; a multiple is a measurement
Estimate years marked E
More audited years; no estimates
MarketPing publishes no forecasts — your own model lives on the Models page
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
